Dr. Osborne is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3410 Worth St
Dallas, TX 75246Phone+1 214-370-1000Fax+1 972-370-1850
Education & Training
University of Texas Medical Branch HospitalsFellowship, Geriatric Medicine (Internal Medicine), 2001 - 2002- University of Texas Medical Branch HospitalsFellowship, Medical Oncology, 1999 - 2001
- University of Texas Medical Branch HospitalsResidency, Internal Medicine, 1996 - 1999
University of Texas Medical Branch School of MedicineClass of 1996
Certifications & Licensure
TX State Medical License 1999 - 2026- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Ixabepilone + Carboplatin Metastatic Breast Cancer Start of enrollment: 2010 Jan 01
- A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
- A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Publications & Presentations
PubMed
- 25 citationsAromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update.Reva Schneider, Ayman Barakat, John Pippen, Cynthia Osborne
Breast Cancer. 2011-10-04 - 28 citationsTrastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis.Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita, Sara A Hurvitz, Shanu Modi
Cancer Discovery. 2022-12-02 - 57 citationsPhase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.Aditya Bardia, Virginia G. Kaklamani, Sharon Wilks, Amy Weise, Donald A. Richards
Journal of Clinical Oncology. 2021-01-29
Press Mentions
Day Care Will Never Be Germ-Free. But We Can Make It Less GrossDecember 16th, 2022- Orally Bioavailable SERD Shows Promise in Certain Breast Cancer PatientsJanuary 31st, 2021
- Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01February 15th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
